FDA PCAC Tracker
The Pharmacy Compounding Advisory Committee voted July 23–24, 2026. Six of the seven peptides were recommended for the 503A Bulks List and emideltide was not. Here is exactly what that means, and what it does not.
On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted on whether to recommend seven peptides for addition to the Section 503A Bulks List — the roster of bulk substances that state-licensed 503A compounding pharmacies may lawfully compound with a valid prescription. It is important to understand what that vote was and was not: PCAC is an advisory body, its recommendations are non-binding, and a vote sits at roughly step two of a roughly six-step federal rulemaking process. Even a unanimous "yes" does not make any compound legally compoundable on its own; that outcome would still require the FDA to complete notice-and-comment rulemaking, a process that realistically takes 12 to 18 months at minimum after a favorable vote.
All seven are currently Category 2. The vote is on whether to recommend moving them toward Category 1 — i.e. toward being legally compoundable with a prescription.
- 1Nomination and intake: A bulk substance is nominated for the 503A Bulks List, and the FDA screens whether the submission contains enough information (chemistry, safety, effectiveness, and history of use) to be evaluated at all.
- 2FDA scientific evaluation: The FDA prepares a review balancing four statutory criteria — physical and chemical characterization, safety concerns in compounded products, evidence of effectiveness or lack thereof, and historical use in compounding — and may consult the U.S. Pharmacopeia (USP).
- 3PCAC advisory vote (where the July 2026 meeting sits): The FDA presented its evaluation to the committee, which discussed each substance and took a public, recorded vote recommending for or against inclusion. This is advisory input only — it does not change the law and does not bind the FDA.
- 4Notice of proposed rulemaking (NPRM): If the FDA elects to move forward, it publishes a proposed rule in the Federal Register identifying which substances it proposes to add to (or exclude from) the list.
- 5Public comment and FDA response: The proposed rule opens a public comment period; the FDA reviews and responds to comments, which can alter, delay, or halt a substance's path.
- 6Final rule: The FDA publishes a final rule that formally establishes whether a substance is added to the 503A Bulks List. Only at this final step does a substance actually become compoundable under 503A.
If the committee votes YES
- ›A YES vote is a formal, non-binding recommendation from the advisory committee that the FDA add the peptide to the 503A Bulks List (moving it from Category 2 toward Category 1).
- ›It signals that a majority of the committee found the available chemistry, safety, effectiveness, and historical-use evidence sufficient to support inclusion.
- ›It does NOT make the compound legal to compound — nothing about a pharmacy's or vendor's legal status changes on the day of the vote.
- ›It does NOT bind the FDA. The agency can decline to adopt the recommendation, propose narrower conditions, or take no action.
- ›It does NOT skip rulemaking. The compound would still need to pass through a proposed rule, a public comment period, and a final rule before becoming compoundable.
- ›Realistic timeline to actual legal compounding availability remains 12 to 18 months minimum after a favorable vote, and there is no guarantee the process reaches a final rule.
If the committee votes NO
- ›A NO vote is an advisory recommendation against adding the peptide to the 503A Bulks List at this time.
- ›The compound remains Category 2 — meaning it may not be compounded under 503A because the available data are considered insufficient or raise significant safety concerns — and stays non-compoundable pending further review.
- ›As with a yes vote, a no vote is non-binding; the FDA is not required to follow it and retains discretion over next steps.
- ›A no vote is not necessarily permanent: a substance can be re-examined if new safety, effectiveness, or characterization data are submitted and the FDA elects to revisit it in a future review cycle.
A second batch is expected February 2027
A second PCAC batch of five additional compounds is expected in February 2027, evaluated on a separate track from the July 2026 docket. These are additional Category 2 peptides scheduled for a later review cycle, and they will move through the same multi-step process: FDA scientific evaluation, an advisory (non-binding) PCAC vote, and — only if the agency proceeds — a proposed rule, public comment, and final rule. Nothing about this second batch is compoundable in the interim, and its own realistic timeline to any potential legal compounding availability would likewise run at least 12 to 18 months beyond a favorable February 2027 vote.